Freshford Capital Management buys $23,348,105 stake in The Advisory Board Company (ABCO)

The Advisory Board Company (ABCO) : Freshford Capital Management scooped up 163,782 additional shares in The Advisory Board Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 710,749 shares of The Advisory Board Company which is valued at $23,348,105.The Advisory Board Company makes up approximately 7.44% of Freshford Capital Management’s portfolio.

Other Hedge Funds, Including , Redmond Asset Management boosted its stake in ABCO in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 20,461 shares of The Advisory Board Company which is valued at $672,144. The Advisory Board Company makes up approx 0.34% of Redmond Asset Management’s portfolio. First Trust Advisors Lp added ABCO to its portfolio by purchasing 33,059 company shares during the most recent quarter which is valued at $1,205,001. Capital Fund Management S.a. added ABCO to its portfolio by purchasing 6,100 company shares during the most recent quarter which is valued at $242,170. Cortland Associates Incmo added ABCO to its portfolio by purchasing 130,429 company shares during the most recent quarter which is valued at $5,440,194. The Advisory Board Company makes up approx 1.11% of Cortland Associates Incmo’s portfolio.

The Advisory Board Company opened for trading at $35.85 and hit $36.95 on the upside on Monday, eventually ending the session at $35.95, with a gain of 0.70% or 0.25 points. The heightened volatility saw the trading volume jump to 4,97,211 shares. Company has a market cap of $1,443 M.

On the company’s financial health, The Advisory Board Company reported $0.28 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Nov 1, 2016. Analyst had a consensus of $0.40. The company had revenue of $200.50 million for the quarter, compared to analysts expectations of $203.35 million. During the same quarter in the previous year, the company posted $0.33 EPS.

Many Wall Street Analysts have commented on The Advisory Board Company. The Advisory Board Company was Downgraded by BofA/Merrill to ” Underperform” on Nov 7, 2016. Shares were Reiterated by Stifel on Nov 2, 2016 to “Hold” and Lowered the Price Target to $ 43 from a previous price target of $45 .

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues including physician alignment and engagement network management and growth strategy value-based care and population health revenue cycle clinical operations and supply chain. Its higher education programs support colleges and universities in enrollment management academic programming and student learning faculty recruitment and retention student advising and success alumni affairs and advancement and college and university operations. The Company offers approximately 65 distinct membership programs across four areas which include best practices research and insight performance technology software consulting and management services and data- and tech-enabled services. Its best practices research and insight programs provide the foundation for all of its other programs.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

The Advisory Board Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on The Advisory Board Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.